Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 92.9%

Neg 92.9% Neu 0% Pos 0%

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.